arrow
P

Peter G. M. Mol

university medical center groningen
H指数:31
被引数:3,122

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Toward the Use of Real-World Data for Regulatory and HTA Decision-Making: Experiences and Recommendations from Six EU-Funded Projects

面向真实世界数据在监管和HTA决策制定中的应用:六个欧盟资助项目的经验与建议

2026-10-220
OA
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data

评估晚期癌症总生存获益:外部对照队列研究结合真实世界数据的作用

2026-02-110
OAAI
The European Medicines Agency's review of elexacaftor/ tezacaftor/ivacaftor: extending its use to all people with cystic fibrosis aged 2 years and older who do not have two class I CFTR variants

欧洲药品管理局对Kaftrio(elexacaftor-tezacaftor-ivacaftor)的审查:将其适用范围扩展至所有年龄在2岁及以上且不携带两种class I CFTR变异的CF患者。

2026-01-011
PRE
Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

射血分数降低的心力衰竭伴慢性阻塞性肺疾病患者中的β受体阻滞剂:心血管和呼吸结局

2025-09-110
OAAI
Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real-World Data Sources for Fit-for-Purpose Studies

导航现实世界:关于有效识别、评估和选择适合特定目的研究现实世界数据来源的结构化框架的范围综述

2025-07-020
OAAI
Timing of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure

心力衰竭患者稳定药物治疗后的心脏再同步治疗时机

2025-06-200
OAAI
Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop

优化患者登记系统以支持监管决策制定——来自HMA/EMA多利益相关方研讨会的关键经验

2025-06-020
OAAI